Home / Content / B2B Connect / Pharma / Dr Reddy's Laboratories launches cholesterol lowering drug in US

Dr Reddy's Laboratories launches cholesterol lowering drug in US

The drug is the generic version of MSD International's Vytorin (ezetimibe & simvastatin) tablet

Dr Reddy's completes acquisition of product portfolio from Teva

premium

Last Updated : May 02 2017 | 1:29 PM IST

Dr Reddy’s Laboratories Ltd has launched cholesterol lowering drug - ezetimibe and simvastatin tablet in strengthens of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg - in the US. The drug is the generic version of MSD International GmbH’s Vytorin tablet. Dr Reddy’s is among the first companies to launch the generic product in the US market.

The Vytorin brand had US sales of approximately $ 678 million MAT for the most recent twelve months ended in February 2017 according to IMS Health. Vytorin reduces the levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in blood, while increasing levels of good cholesterol (high-density lipoprotein, or HDL).

Dr Reddy’s ezetimibe and simvastatin tablets will be available in bottle count sizes of 30, 90 and 1000.